ACTIPATCH/RECOVERYRX IS THE SOLUTION - JUST NEED TO FIGURE

New Post Public Reply Private Reply Replies (0) Message Board
Bielionaire
255
ACTIPATCH/RECOVERYRX IS THE SOLUTION - JUST NEED TO FIGURE OUT HOW TO LET THE WORLD KNOW!!!
Actipatch/RecoveryRX can change the "entrenched culture" that Dr. Ballantyne refers to below!

Healio - February 20, 2025 - 2 min read

New recommendations urge against spine injections for chronic back pain
ByAndrew (Drew) Rhoades
Fact checked byCarol L. DiBerardino, MLA, ELS

Key takeaways:
An international panel found no high certainty evidence on conventional procedures for spine pain.
The panel concluded that such procedures are costly, burdensome and do not provide meaningful relief.
Spine injections should not be given to adults with chronic back pain because they provide little or no pain relief vs. sham injections, according to new clinical practice guidelines.

The recommendations, published in BMJ and developed in partnership with the nonprofit MAGIC group, apply to adults with moderate to severe chronic axial or radicular spine pain that is not related to cancer and has lasted for at least 3 months.

An international panel found no high certainty evidence on conventional procedures like epidural injections for spine pain.
Low back pain remains the leading worldwide cause of years lived with disability, while such pain could impact more than 800 million people by 2050.

According to Jason W. Busse, DC, PhD, a professor at McMaster University in Canada, and colleagues, current procedures for low back pain like nerve blocks, nerve ablation and epidural injections are being increasingly used, but evidence is lacking to support the efficacy of these treatments.

An international panel made up of 10 clinicians, eight methodologists and four people living with chronic back pain conducted an analysis of evidence on procedures using the Grading of Recommendations Assessment, Development and Evaluation approach.

The panel compared the benefits and harms of 13 interventional procedures or combinations of procedures for chronic, noncancer back pain against sham treatments using the data of a systematic review and meta-analysis on randomized trials and observational studies.

Procedures that were assessed included:

epidural injections of local anesthetic, steroids or a combination;
injections of local anesthetic, steroids or a combination; and
radiofrequency ablation with or without local anesthetic plus steroid injections.

No high certainty evidence found
The panel concluded that there was no high certainty evidence for any of the procedures or combinations of procedures, while low and moderate certainty evidence indicate that spine injections would provide no meaningful relief for pain in a specific area of the spine or pain radiating from the spine to the arms or legs compared with sham injections.

The procedures are costly, “burdensome and may result in adverse events,” the experts wrote, adding that almost all informed patients would choose to forgo them due to the little or no benefit received.

The panel noted that there are several remaining questions that future research could attempt to answer, such as if there are systematic differences in treatment effects of interventional procedures based on subtypes of chronic spine pain and what the effects treatments may have on patient outcomes — which were poorly reported in trials — like returning to work, sleep quality, mental functioning and opioid use.

Independent analysis
In an accompanying editorial, Jane C. Ballantyne, MD, FRCA, an anesthesiologist at the University of Washington Medical Center, explained that the guidance raises the question of whether such treatments should still be offered to those with chronic back pain.

“It is never easy to change entrenched culture, and injections have undoubtedly become entrenched as a key component of pain clinic treatments,” she wrote.

One way to change the behavior of patients and physicians when it comes to these treatments “is through financial incentive,” Ballantyne added.

“Yes, there are many pressures on providers to keep doing spine injections, and on payers to keep paying for them, but the more the evidence fails to support the widespread use of these injections, the less inclined health care systems will be to fund them.”

From another publication (BMJ):
Experts strongly recommend against spine injections for chronic back pain
Commonly used injections offer little or no pain relief, says expert panel
Findings question whether it’s reasonable to continue to offer these procedures outside of clinical trials

Spine injections should not be given to adults with chronic back pain because they provide little or no pain relief compared with sham injections, say a panel of international experts in The BMJ today.

Their strong recommendations apply to procedures such as epidural steroid injections and nerve blocks for people living with chronic back pain (lasting at least 3 months) that is not associated with cancer, infection or inflammatory arthritis.

Their advice is based on the latest evidence and is part of The BMJ’s ‘Rapid Recommendations’ initiative – to produce rapid and trustworthy guidance based on new evidence to help doctors make better decisions with their patients.

Chronic back pain is the leading cause of disability worldwide. It is estimated to affect 1 in 5 adults aged 20-59, with higher rates likely among older adults. In 2016, low back and neck pain accounted for the highest healthcare spending in the US at $134.5 billion.

Procedures such as epidural steroid injections, nerve blocks and radiofrequency ablation (using radio waves to destroy nerves) are widely used to stop pain signals reaching the brain, but current guidelines provide conflicting recommendations for their use.

So an international panel, made up of clinicians, people living with chronic spine pain, and research methodologists, carried out a detailed analysis of the latest evidence using the GRADE approach (a system used to assess the quality of evidence).

This evidence, based on reviews of randomised trials and observational studies, compared the benefits and harms of 13 common interventional procedures, or combinations of procedures, for chronic, non-cancer spine pain against sham procedures.

After careful consideration, the panel concluded that there was no high certainty evidence for any procedure or combination of procedures, and all low and moderate certainty evidence suggests no meaningful relief for either axial pain (in a specific area of the spine) or radicular pain (radiating from the spine to the arms or legs) for spine injections compared with sham procedures. As such, they strongly recommend against their use.

This includes injections of local anaesthetic, steroids, or their combination; epidural injections of local anaesthetic, steroids, or their combination; and radiofrequency ablation with or without local anaesthetic plus steroid injections.

The panel added that these procedures are costly, a burden on patients, and carry a small risk of harm. As such, they say almost all informed patients would choose to avoid them.

Finally, they acknowledge that further research is warranted and may alter future recommendations, in particular for procedures currently supported by only low or very low certainty evidence of effectiveness. Further research is also needed to establish the effects of interventional procedures on important outcomes for patients such as opioid use, return to work, and sleep quality.

In a linked editorial, Jane Ballantyne at the University of Washington says the question this recommendation raises is whether it is reasonable to continue to offer these procedures to people with chronic back pain.

It is never easy to change entrenched culture, she writes, “but the more the evidence fails to support the widespread use of these injections, the less inclined healthcare systems will be to fund them.”

“This will not be the last word on spine injections for chronic back pain, but it adds to a growing sense that chronic pain management needs a major rethink that is perhaps best achieved by a better balance of reimbursements between procedural and non-procedural chronic pain treatments,” she concludes.

20/02/2025

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Future FinTech Under Investigation: Shareholder Impact Looms

Updated Category News Views 81

Future FinTech Faces Legal Scrutiny When the walls close in under financial suspicion, the spotlight can burn brighter than any anticipated market gain. That's precisely what Future FinTech Group Inc. (NasdaqCM: FTFT) is up against now. Kahn Swick & Foti, LLC, featuring the ex-Attorney General of Louisiana, Charles C. Foti, Jr., has begun scrutinizing the actions of...

Continue Reading
Paris Baguette Pioneers Drive-Thru in Oklahoma

Updated Category News Views 192

Tapping The Unseen Potential In Bakery Cafes Every so often a business move comes along that makes you sit up and say, "Why the hell haven't they done this before?" Paris Baguette has finally cracked that code, rolling out its first-ever drive-thru in Moore, Oklahoma. Now, imagine yourself zipping through for a croissant without leaving the comfort of your car seat. Makes...

Continue Reading
Sussex County Data Breach Raises Security Concerns

Updated Category News Views 136

The Digital Fiasco: A Wake-Up Call Straight out of Sussex County in good ol' New Jersey, we’re staring down another data breach, folks. When you hear about a data privacy incident, there's always that same sinking feeling of another layer of personal security peeled away. This time, the Sussex County Prosecutor's Office got caught in the crossfire, with personal info...

Continue Reading
Datavault AI's Turbulent Boardroom Saga Escalates

Updated Category News Views 215

The Corporate Chess Game at Datavault AI If there's one thing Wall Street hates, it's uncertainty. And boy, does Datavault AI (NASDAQ: DVLT) deliver plenty of it right now. Founder Nathaniel Bradley has lobbed a lawsuit at the board, claiming that Chairman and CFO Brett Moyer orchestrated a coup to oust him without proper board procedures. Talk about drama fit for a soap...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 58

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 184

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
DraftKings Faces Revenue Cutback; Legal Probe Begins

Updated Category News Views 180

DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...

Continue Reading
Koppers Faces Investigation: Investors Cautious Amid Probe

Updated Category News Views 211

Deep Dive: Koppers' Financial Turmoil When a company throws a financial party, you don't expect the hangover to come in the form of an investigation notice. That’s what’s brewing over at Koppers Holdings Inc., leading many seasoned investors to take a hard, scrutinizing look at the books. The latest buzz? An inquiry into whether the company gave its investors the full...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 212

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 151

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading

Top 5 Most Recently Viewed Articles

UPS Expands Healthcare Logistics with Frigo-Trans and BPL Acquisitions

Updated Category News Views 176

UPS Enhances Healthcare Logistics Solutions UPS (NYSE: UPS) has recently completed a strategic acquisition that elevates its healthcare logistics services significantly. By acquiring Frigo-Trans and its sister company, BPL, UPS is set to bolster its capabilities in providing complex logistics solutions for the healthcare industry across Europe. Broader Reach in Cold-Chain...

Continue Reading
Dr. Teck Lim Chia's Recognition for Excellence in Leadership

Updated Category News Views 125

Dr. Teck Lim Chia’s Recognition at Directors of the Year Awards CBL International Limited (NASDAQ: BANL) has proudly acknowledged the remarkable achievement of Dr. Teck Lim Chia, its Chairman and CEO, who has been honored at the Directors of the Year Awards presented by the Hong Kong Institute of Directors. This prestigious recognition places Dr. Chia in the spotlight...

Continue Reading
Investors Seek Justice as Faruqi & Faruqi Addresses Cytokinetics

Updated Category News Views 225

Justice for Cytokinetics Investors: A Call to Action Faruqi & Faruqi, LLP, a respected name in the realm of national securities law, is taking significant steps to support investors of Cytokinetics, Incorporated (NASDAQ: CYTK). Those who faced losses due to investments in Cytokinetics are encouraged to reach out to the firm for a discussion on possible legal avenues for...

Continue Reading
Transforming Stadium Cleaning with Innovative Data Solutions

Updated Category News Views 167

Innovative Partnership to Elevate Stadium Cleanliness Pritchard Sports and Entertainment Group, a leader in facility services, has joined forces with TRAX Analytics, a frontrunner in janitorial technology. This powerful partnership aims to enhance cleanliness and efficiency at major sports and entertainment venues. Revolutionizing Cleaning Practices The newly formed...

Continue Reading
Biohaven Faces Class Action Lawsuit Amid Concerns of Misleading Claims

Updated Category News Views 187

Understanding the Class Action Against Biohaven Ltd. Pomerantz LLP, a prominent law firm, has announced a significant legal action against Biohaven Ltd. (NYSE: BHVN) and certain of its officials. This class action lawsuit has been initiated to address investor concerns that arose during a specific time frame where certain securities were acquired. The lawsuit, filed in...

Continue Reading